(NASDAQ: AVTE) Aerovate Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 13.98%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 18.94%.
Aerovate Therapeutics's earnings in 2025 is -$84,611,000.On average, 2 Wall Street analysts forecast AVTE's earnings for 2025 to be -$24,254,591, with the lowest AVTE earnings forecast at -$32,916,945, and the highest AVTE earnings forecast at -$15,592,237. On average, 2 Wall Street analysts forecast AVTE's earnings for 2026 to be -$13,571,021, with the lowest AVTE earnings forecast at -$19,634,669, and the highest AVTE earnings forecast at -$7,507,373.
In 2027, AVTE is forecast to generate -$20,212,159 in earnings, with the lowest earnings forecast at -$20,212,159 and the highest earnings forecast at -$20,212,159.